Articles

Applying its priority review route, the FDA approved the biologic medication ipilimumab (Yervoy; Bristol-Myers Squibb) as a second-line therapy for the treatment of patients with unresectable or metastatic melanoma.

Interview with Al B. Benson, III, MD, FACP

Both practice guidelines and thought leaders increasingly recommend biomarker tests for optimization of cancer care; there is, however, a gap between these recommendations, the way physicians practice, and the way they think they practice.

At the request of the US Secretary of Health and Human Services, the Institute of Medicine (IOM) will conduct a study on national variation in healthcare spending and utilization for individuals with Medicare, Medicaid, private insurance, or no insurance.